Related references
Note: Only part of the references are listed.Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study
Antoinette O'Connor et al.
MOLECULAR PSYCHIATRY (2021)
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative
Thomas K. Karikari et al.
MOLECULAR PSYCHIATRY (2021)
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Joel Simren et al.
ALZHEIMERS & DEMENTIA (2021)
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum
Alexis Moscoso et al.
BRAIN (2021)
Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative
Anna Zettergren et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
Alexis Moscoso et al.
JAMA NEUROLOGY (2021)
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology
Nicholas J. Ashton et al.
ACTA NEUROPATHOLOGICA (2021)
Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art
Samir Abu-Rumeileh et al.
FRONTIERS IN NEUROSCIENCE (2021)
Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study
Yan-Li Wang et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Carolin Heller et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H. Thijssen et al.
NATURE MEDICINE (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Nicolas R. Barthelemy et al.
NATURE MEDICINE (2020)
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
James D. Doecke et al.
NEUROLOGY (2020)
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
Juan Lantero Rodriguez et al.
ACTA NEUROPATHOLOGICA (2020)
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
Niklas Mattsson-Carlgren et al.
BRAIN (2020)
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected
Marc Suarez-Calvet et al.
EMBO MOLECULAR MEDICINE (2020)
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
Xue-Ning Shen et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2020)
Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment
Avinash Chandra et al.
JOURNAL OF NEUROLOGY (2019)
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Anja Soldan et al.
NEUROLOGY (2019)
Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
Simone Baiardi et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
Inge M. W. Verberk et al.
ANNALS OF NEUROLOGY (2018)
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease
Piotr Lewczuk et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Current state of Alzheimer's fluid biomarkers
Jose Luis Molinuevo et al.
ACTA NEUROPATHOLOGICA (2018)
Tau plasma levels in subjective cognitive decline: Results from the DELCODE study
Stephan Mueller et al.
SCIENTIFIC REPORTS (2017)
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia
Tobias Skillback et al.
BRAIN (2015)
Neurofilament light chain A prognostic biomarker in amyotrophic lateral sclerosis
Ching-Hua Lu et al.
NEUROLOGY (2015)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tero Tapiola et al.
ARCHIVES OF NEUROLOGY (2009)
Neurochemical aftermath of amateur boxing
Henrik Zetterberg et al.
ARCHIVES OF NEUROLOGY (2006)
Share Paper
